Quinazoline-based anti-virulence compounds selectively target Salmonella PhoP/PhoQ signal transduction system.
The rapid emergence of multi-drug resistance among bacterial pathogens has become a significant chal lenge to human health in our century. Therefore, development of next-generation anti-bacterial com pounds is an urgent need. Two-component signal transduction systems (TCS) are stimulus-response coupling devices that allow bacteria to sense and elaborate adaptive responses to changing environmental conditions, including the challenges that pathogenic bacteria face inside the host. The differential presence of TCS, present in bacteria but absent in the animal kingdom, makes them attractive targets in the search for new antibacterial compounds. In Salmonella enterica, the PhoP/PhoQ two-component system controls the expression of crucial phenotypes that define the ability of the pathogen to establish infection in the host. We now report the screening of 686 compounds from the GlaxoSmithKline Published Kinase Inhibitor Set in a high throughput whole-cell assay that targets Salmonella Typhimurium PhoP/PhoQ. We identify a series of quinazoline compounds that show selective and potent down regulation of PhoP/PhoQ-activated genes and define structural attributes required for their efficacy. We demonstrate that their bioactivity is due to repression of the PhoQ sensor autokinase activity by interaction with its catalytic domain, acting as competitive inhibitors of ATP binding. While being noncytotoxic, the hit molecules exhibit anti-virulence effect by blockage of S. Typhimurium intramacrophage replication. Together, these features make these quinazoline compounds stand out as exciting leads to develop a therapeutic intervention to fight salmonellosis.